|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-1.11/-0.59
|
企業價值
324.05M
|
資產負債 |
每股賬面淨值
0.78
|
現金流量 |
現金流量率
--
|
損益表 |
收益
299.49M
|
每股收益
0.56
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/11 09:57 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment include Consumer and Research Services and Therapeutics. The company generatesmaximum revenue from the Consumer and Research Services segment. |